Delamanid, a New Drug for Multi-Drug Resistant Tuberculosis (MDR-TB), and Efavirenz Do Not Show Clinically Relevant Drug Interactions in Healthy Subjects

Trial Profile

Delamanid, a New Drug for Multi-Drug Resistant Tuberculosis (MDR-TB), and Efavirenz Do Not Show Clinically Relevant Drug Interactions in Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 18 Sep 2012

At a glance

  • Drugs Delamanid (Primary) ; Efavirenz
  • Indications HIV infections; Tuberculosis
  • Focus Pharmacokinetics
  • Most Recent Events

    • 18 Sep 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top